Front-line and health care workers will get the vaccine first. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Four sites in Texas received the COVID-19 vaccine on December 14, part of a rollout of doses being shipped out across the U.S.

Texas received 19,500 doses, with another 250,000 doses being distributed to 109 facilities in Texas this week.

According to the Texas Department of State Health Services, the first four sites to get it were:

  • MD Anderson Cancer Center in Houston
  • Methodist Dallas Medical Center
  • Wellness 360 at UT Health San Antonio
  • UT Health Austin's Dell Medical School

Another 75,000 doses will be delivered on December 15 to 19 sites in Texas:

  • Houston, Texas Children's Hospital Main
  • Houston, LBJ Hospital
  • Houston, CHI St. Luke's Health
  • Houston, Memorial Hermann Texas Medical Center
  • Houston, Houston Methodist Hospital
  • Houston, Ben Taub General Hospital
  • Galveston, University of Texas Medical Branch Hospital
  • Amarillo, Texas Tech Univ. Health Science Center Amarillo
  • Corpus Christi, Christus Spohn Health System Shoreline
  • Dallas, Parkland Hospital
  • Dallas, UT Southwestern
  • Edinburg, Doctors Hospital at Renaissance
  • Edinburg, UT Health RGV Edinburg
  • El Paso, University Medical Center El Paso
  • Fort Worth, Texas Health Resources Medical Support
  • Lubbock, Covenant Medical Center
  • San Angelo, Shannon Pharmacy
  • Temple, Baylor Scott and White Medical Center

Health care and front-line workers will receive the vaccine first. Officials are still working out the timeline but the general public is not expected to get the vaccine until spring 2021 at the earliest.

Dr. Paul Klotman, president of the Baylor College of Medicine in Houston, said in a press conference that getting vaccinated is helpful to both individuals and their communities.

"The thing about everyone pitching in, do it for yourself because it will help protect you, but when you get the herd immunity it will help protect people who are unable medically to get the vaccine," Klotman said.

------

This article originally ran on CultureMap.

This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care.

Sola Lawal, product operations manager at Nuro

Autonomous vehicle delivery service is driving access to food in Houston’s vulnerable communities

Native Houstonian Sola Lawal is looking into how AI and robotics can help increase access to fresh foods in local food deserts. Photo courtesy of Nuro

Sola Lawal has always found himself back in his hometown of Houston. Now working for artificial intelligence and robotics company, Nuro, he sees the potential Houston has to become a major market for autonomous vehicles.

"I think that autonomous vehicles are going to become an industry in the same way your standard vehicles are," Lawal says."One really strong way the Houston ecosystem and Nuro can partner is essentially building out the ancillary."

Lawal shared more on how Houston and Nuro can work together on this week's episode of the Houston innovators podcast. Read more and stream the episode.

Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

A new, portable ultrasound device has equipped Jose Diaz-Gomez and his team with a reliable, easy-to-use tool for diagnostics and tracking progress of COVID-19 patients. And this tool will continue to help Diaz-Gomez lead his team of physicians.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography." Read more.

Kimberly A. Baker, assistant professor at UTHealth School of Public Health

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

It was unnerving to Kimberly Baker that proper sex education wasn't in the curriculum of Texas schools, and women were left without resources for contraceptives. So, along with UTHealth School of Public Health, she launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker. Continue reading.

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

Houston hospital taps new tech to provide more accurate COVID-19 diagnostics and treatment

hand held

With such a dynamic virus like COVID-19 that affects patients with different levels of severity, the first challenge doctors face when treating infected patients is assessing the situation. CHI St. Luke's Health has been implementing a new technology that allows its physicians better access to that initial diagnosis.

Dr. Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health and ultrasonography expert, says the Butterfly iQ's portable ultrasonography technology has been a key tool in his team's point of care for COVID-19 patients. Over the past few years, ultrasonography equipment has been evolving to be more portable and more accurate. That's what the Butterfly iQ technology provides, and Diaz-Gomez says his team was quick to realize how the technology can help in diagnostics and treatment of coronavirus patients.

A traditional approach to examining a patient's lungs would mean radiography, but Diaz-Gomez says his team saw the opportunity ultrasonography and these new, portable devices had on providing more accurate and timely diagnostics.

"In conditions that are dynamic, you want to have a diagnostic tool that, over time as you're treating a patient, you can see meaningful changes — good or bad," Diaz-Gomez says. "The pandemic has enabled us to use — from the initial care to when they are on the ventilator — ultrasonography to see the changes in the patient's' lungs."

Jose Diaz-Gomez is an anesthesiologist at CHI St. Luke's. Photo courtesy of CHI St. Luke's

The Butterfly iQ device is different from its ultrasound predecessors in that it's built to be more accurate, portable, easy to use, and low cost (even being made available for commercial purchase). According to Diaz-Gomez, he could train someone on the device in just a few hours.

Ahead of the pandemic, CHI St. Luke's had 20 of these devices and now has doubled that initial fleet. Along with the other non-Butterfly iQ ultrasonography devices, Diaz-Gomez's team has access to 70 ultrasonography devices — 80 percent of which are dedicated to COVID-19 patients.

"Our institution was very supportive of bringing a very robust roll-out program for point-of-care ultrasonography during the pandemic," Diaz-Gomez says. "We were able to incorporate 40 ultrasound devices — the Butterfly system. Not only that, we actually implemented a very rigorous infection control process to make sure we do it in a safe manner. You don't want to bring tools that will be another source of transmission from patient to patient."

While this new technology is continuing to make a difference in St. Luke's COVID units, Diaz-Gomez is already looking forward to the difference the devices will make post pandemic.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography."

The device, with its portability, low cost, and ease of use, also has an application for telemedicine and at-home health, and that's something that's exciting for Diaz-Gomez. However, both in his COVID units or in the home setting, the device is only as good as the clinician who's interpreting the images paired with the other diagnostics.

"The integration of ultrasonography with the clinical practice itself — it has to go hand in hand," Diaz-Gomez says. "The clinical decision will depend on that integration."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.

4 Houston-area schools excel with best online degree programs in U.S.

Top of the Class

Four Houston-area universities have earned well-deserved recognition in U.S. News & World Report's just-released rankings of the Best Online Programs for 2026.

The annual rankings offer insight into the best American universities for students seeking a flexible and affordable way to attain a higher education. In the 2026 edition, U.S. News analyzed nearly 1,850 online programs for bachelor's degrees and seven master's degree disciplines: MBA, business (non-MBA), criminal justice, education, engineering, information technology, and nursing.

Many of these local schools are also high achievers in U.S. News' separate rankings of the best grad schools.

Rice University tied with Texas A&M University in College Station for the No. 3 best online master's in information technology program in the U.S., and its online MBA program ranked No. 21 nationally.

The online master's in nursing program at The University of Texas Medical Branch in Galveston was the highest performing master's nursing degree in Texas, and it ranked No. 19 nationally.

Three different programs at The University of Houston were ranked among the top 100 nationwide:
  • No. 18 – Best online master's in education
  • No. 59 – Best online master's in business (non-MBA)
  • No. 89 – Best online bachelor's program
The University of Houston's Clear Lake campus ranked No. 65 nationally for its online master's in education program.

"Online education continues to be a vital path for professionals, parents, and service members seeking to advance their careers and broaden their knowledge with necessary flexibility," said U.S. News education managing editor LaMont Jones in a press release. "The 2026 Best Online Programs rankings are an essential tool for prospective students, providing rigorous, independent analysis to help them choose a high-quality program that aligns with their personal and professional goals."

A little farther outside Houston, two more universities – Sam Houston State University in Huntsville and Texas A&M University in College Station – stood out for their online degree programs.

Sam Houston State University

  • No. 5 – Best online master's in criminal justice
  • No. 30 – Best online master's in information technology
  • No. 36 – Best online master's in education
  • No. 77 – Best online bachelor's program
  • No. 96 – Best online master's in business (non-MBA)
Texas A&M University
  • No. 3 – Best online master's in information technology (tied with Rice)
  • No. 3 – Best online master's in business (non-MBA)
  • No. 8 – Best online master's in education
  • No. 9 – Best online master's in engineering
  • No. 11 – Best online bachelor's program
---

This article originally appeared on CultureMap.com.